SAN FRANCISCO, February 1, 2016 /PRNewswire/ --
Global IVD infectious disease market is expected to reach 25.9 billion by 2022 according to a new report by Grand View Research Inc. Introduction of technologically advanced diagnostic devices along with associated benefits such as rapid result availability, improved accuracy, ease of usage, and cost-effectiveness is expected to serve this market as high-impact rendering drivers over the forecast period. For instance, Abbott Molecular has introduced a new range of real-time assays for HBV and HCV infections on its m200 platform.
(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )
Rising level of epidemics of communicable diseases such as H1N1 and Ebola virus is of growing concern in low-income countries. These diseases are reported to play a significant role in causing mortality in developing regions.
Browse full research report with TOC on "IVD Infectious Disease Market Analysis By Product (Instruments, Reagents, Software), By Technology, Application (MRSA, Streptococcus, Clostridium difficile, Vancomycin-resistant enterococci, Carbapenem-resistant bacteria testing, Respiratory virus, Candida, Tuberculosis and drug-resistant TB, Gastro-intestinal panel testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B), By Test Location And Segment Forecasts To 2022" at: http://www.grandviewresearch.com/industry-analysis/ivd-infectious-disease-market
Low level of hygiene, less awareness levels, and social taboo for early testing are some of the drivers leading to increasing share of target population in low-income countries. According to the WHO, number of cases has increased by around 1 million each year with over 357 million people already suffering from one of the four types of STI. It is also estimated that over 290 million women are having HPV infection and over 25% of them are unaware of the infection.
Further key findings from the report suggest:
- Reagents were one of the significant share holders of the IVD infectious disease market with the market size over USD 8,900 million. Wide range of available kits and extensive use of chemical reagents are estimated to be key factors for large market share.
- However, instruments owing to their speed, sensitivity, and ability to diagnose multiple samples in a single run will witness significant growth rate over the decade.
- Immunochemistry is one of the most conventional methods for infectious disease testing. ELISA is one of the leading technologies with market share of over 33.0%. Cost-effectiveness, large amount of kits available from key players, and ease-of-usage are high-impact rendering drivers.
- Molecular diagnostics is anticipated to witness the fastest growth over 9.0% owing to its increasing usage rates and improved accuracy levels will affect the market share of other technologies and
- High amount of target population, increasing prevalence at a very high rate, and favorable government initiatives for preventive care are key factors for making HIV one of the most common infectious diseases. Self-testing kits are introduced by many companies, such as Insti HIV by BioSURE, for early diagnosis and future prevention.
- Central Laboratories owing to its established infrastructure, presence of skilled man force, and ability to handle high procedure volumes dominated the test location segment in 2014. PoC testing market on the other hand is anticipated to grow at a lucrative rate of 10.3% owing to increasing base of self-conscious population coupled with rising demand for rapid testing.
- In 2014, North America dominated the overall IVD infectious disease market. Growing prevalence of infectious diseases, rising levels of patients and healthcare professionals, and favorable government initiatives for IVD diagnostic tests are factors attributing to the major share of this market.
- China is expected to register lucrative growth over the forecast period with a CAGR of over 17.0% due to presence of improving healthcare infrastructure, presence of high unmet clinical needs, and rising economic levels. Moreover, growing demand for portable and rapid devices for early diagnosis is expected to provide potential growth platform for key market players.
- Major companies such as Roche Diagnostics, Abbott Molecular, and Becton Dickinson are investing a huge amount in R&D of diagnostic kits pertaining to novel infectious diseases biomarkers. These companies are more focused in the development of kits compatible with their instruments in an attempt to stabilize their market position.
Grand View Research has segmented the IVD infectious diseases market on the basis of product, technology, application, test location, and region:
- Global In-Vitro Diagnostics (IVD) Infectious Disease Product Outlook, Revenue (USD Million, 2015 - 2022)
- IVD infectious disease Instruments
- IVD infectious disease Reagents
- Software
- Global In-Vitro Diagnostics (IVD) Infectious Disease Technology Outlook, Revenue (USD Million, 2015 - 2022)
- Immunochemistry
- Microbiology
- Molecular diagnostics
- Global In-Vitro Diagnostics (IVD) Infectious Disease Application Outlook, Revenue (USD Million), 2015 - 2022
- MRSA
- Streptococcus
- Clostridium difficile
- Vancomycin-resistant enterococci
- Carbapenem-resistant bacteria testing
- Respiratory virus
- Candida
- Tuberculosis and drug-resistant TB
- Gastro-intestinal panel testing
- Chlamydia
- Gonorrhea
- HPV
- HIV
- Hepatitis C
- Hepatitis B
- Other Infectious Diseases
- Global In-Vitro Diagnostics (IVD) Infectious Disease Test Location Outlook, Revenue (USD Million, 2015 - 2022)
- Point of Care
- Central Laboratories
- Others
- In-Vitro Diagnostics (IVD) Infectious Disease Regional Outlook, by Revenue (USD Million, 2015 - 2022)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Browse related reports by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Read Our Blogs - mediafound.org, ni2014.org
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com
Share this article